HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.

AuthorsAndres Forero-Torres, Nancy L Bartlett, Robert B Berryman, Robert Chen, Jeffrey V Matous, Michelle A Fanale, Owen A O'Connor, Randal Olshefski, Scott E Smith, Dirk Huebner, Pamela L Levine, Laurie E Grove, Ajay K Gopal
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 56 Issue 4 Pg. 1151-3 (Apr 2015) ISSN: 1029-2403 [Electronic] United States
PMID25110824 (Publication Type: Letter)
Chemical References
  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin
Topics
  • Adolescent
  • Adult
  • Aged
  • Brentuximab Vedotin
  • Drug Administration Schedule
  • Drug Resistance, Neoplasm
  • Fatigue (chemically induced)
  • Female
  • Headache (chemically induced)
  • Hematologic Neoplasms (drug therapy, metabolism)
  • Humans
  • Immunoconjugates (adverse effects, therapeutic use)
  • Infections (chemically induced)
  • Ki-1 Antigen (metabolism)
  • Male
  • Middle Aged
  • Nervous System Diseases (chemically induced)
  • Recurrence
  • Spasm (chemically induced)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: